Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

A real-world, population-based study of the outcomes of patients with metastatic colorectal cancer to the peritoneum treated with or without cytoreductive surgery

  • 29 Accesses



To assess the outcomes of metastatic colorectal cancer patients with isolated peritoneal metastasis who were treated with or without cytoreductive surgery in a contemporary real-world, population-based cohort.


Surveillance, Epidemiology, and End Results (SEER) database has been accessed and metastatic colorectal cancer patients to the peritoneum who have no evidence of other sites of distant metastases and who were diagnosed 2010–2015 were reviewed. Multivariable logistic regression analysis was then used to assess the patient- and treatment-related factors predicting the decision to do cytoreductive surgery. Kaplan-Meier survival estimates were used to compare overall survival according to cytoreductive surgery. Multivariable Cox regression analysis was additionally used to assess the impact of cytoreductive surgery on colorectal cancer-specific survival.


A total of 3153 records were reviewed in the current analysis. Using Kaplan-Meier survival estimates, cytoreductive surgery was associated with improved overall survival (median overall survival, 19 months for patients with cytoreductive surgery versus 12 months for patients without cytoreductive surgery; P < 0.001). In an adjusted Cox regression model evaluating the impact of cytoreductive surgery on colorectal cancer-specific survival, cytoreductive surgery was associated with better colorectal cancer-specific survival (hazard ratio for death among patients who did not have cytoreductive surgery versus patients who had cytoreductive surgery, 1.312; 95% CI, 1.175–1.465; P < 0.001).


Cytoreductive surgery is associated with improved survival outcomes among colorectal cancer patients with peritoneal metastasis and no evidence of other distant metastases. Opimal utilization of this intervention needs to be further evaluated in prospective controlled trials.

This is a preview of subscription content, log in to check access.

Fig. 1


  1. 1.

    Al-Husseini MJ, Saad AM, Mohamed HH, Alkhayat MA, Sonbol MB, Abdel-Rahman O (2019) Impact of prior malignancies on outcome of colorectal cancer; revisiting clinical trial eligibility criteria. BMC Cancer 19(1):863. https://doi.org/10.1186/s12885-019-6074-6

  2. 2.

    Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS et al (2017) Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15(3):370–398

  3. 3.

    van de Velde CJ, Aristei C, Boelens PG, Beets-Tan RG, Blomqvist L, Borras JM, van den Broek C, Brown G, Coebergh JW, Cutsem EV, Espin E, Gore-Booth J, Glimelius B, Haustermans K, Henning G, Iversen LH, Han van Krieken J, Marijnen CA, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P, Rödel C, Roth A, Rutten HJ, Schmoll HJ, Smith J, Tanis PJ, Taylor C, Wibe A, Gambacorta MA, Meldolesi E, Wiggers T, Cervantes A, Valentini V, European Registration of Cancer Care (2013) EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. Eur J Cancer 49(13):2784–2790. https://doi.org/10.1016/j.ejca.2013.04.032

  4. 4.

    Leimkühler M, Hemmer PHJ, Reyners AKL, de Groot DJA, van Ginkel RJ, Been LB et al (2019) Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study. World J Surg Oncol 17(1):14. https://doi.org/10.1186/s12957-018-1554-8

  5. 5.

    Canda AE, Arslan C, Terzi C, Sokmen S, Yavuzsen T, Ozkardesler S, Unlu M, Obuz F, Fuzun M (2018) Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy. World J Surg Oncol 16(1):70. https://doi.org/10.1186/s12957-018-1369-7

  6. 6.

    El-Nakeep S, Rashad N, Oweira H, Schmidt J, Helbling D, Giryes A et al (2017) Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review. Expert Rev Gastroenterol Hepatol 11(3):249–258. https://doi.org/10.1080/17474124.2017.1284586

  7. 7.

    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Custom Data (with additional treatment fields), Nov 2018 Sub (1975-2016 varying) - Linked To County Attributes - Total U.S., 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission

  8. 8.

    Abdel-Rahman O (2019) Effect of body mass index on 5-FU-based chemotherapy toxicity and efficacy among patients with metastatic colorectal cancer; a pooled analysis of 5 randomized trials. Clin Colorectal Cancer. https://doi.org/10.1016/j.clcc.2019.07.005

  9. 9.

    Abdel-Rahman O (2019) Impact of sex on chemotherapy toxicity and efficacy among patients with metastatic colorectal cancer: pooled analysis of 5 randomized trials. Clin Colorectal Cancer 18(2):110–5.e2. https://doi.org/10.1016/j.clcc.2018.12.006

  10. 10.

    Abdel-Rahman O (2019) Prognostic value of baseline ALBI score among patients with colorectal liver metastases: a pooled analysis of two randomized trials. Clin Colorectal Cancer 18(1):e61–ee8. https://doi.org/10.1016/j.clcc.2018.09.008

  11. 11.

    Ahmed S, Stewart JH, Shen P, Votanopoulos KI, Levine EA (2014) Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. J Surg Oncol 110(5):575–584. https://doi.org/10.1002/jso.23749

  12. 12.

    Riss S, Mohamed F, Dayal S, Cecil T, Stift A, Bachleitner-Hofmann T, Moran B (2013) Peritoneal metastases from colorectal cancer: patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 39(9):931–937. https://doi.org/10.1016/j.ejso.2013.06.001

  13. 13.

    Luo C, Cen S, Ding G, Wu W (2019) Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commu 39(1):13. https://doi.org/10.1186/s40880-019-0361-0

  14. 14.

    Quirt JS, Nanji S, Wei X, Flemming JA, Booth CM (2017) Is there a sex effect in colon cancer? Disease characteristics, management, and outcomes in routine clinical practice. Curr Oncol 24(1):e15–e23. https://doi.org/10.3747/co.24.3410

  15. 15.

    White A, Ironmonger L, Steele RJC, Ormiston-Smith N, Crawford C, Seims A (2018) A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. BMC Cancer 18(1):906. https://doi.org/10.1186/s12885-018-4786-7

Download references

Author information

Correspondence to Omar Abdel-Rahman.

Ethics declarations

Conflict of interest

The author declares that he has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were following the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

As this study is based on a publicly available database without identifying patient information, informed consent was not needed.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Abdel-Rahman, O. A real-world, population-based study of the outcomes of patients with metastatic colorectal cancer to the peritoneum treated with or without cytoreductive surgery. Int J Colorectal Dis (2020). https://doi.org/10.1007/s00384-020-03525-x

Download citation


  • Colorectal cancer
  • Peritoneal metastasis
  • Surgery
  • Cytoreduction